单核髓源性抑制细胞中FoxO1缺陷加重系统性红斑狼疮的B细胞功能障碍
本研究结合GEO数据集与SLE临床队列,发现FoxO1在SLE患者及狼疮小鼠的单核髓源性抑制细胞(M-MDSCs)中低表达,且与SLE疾病活动指数评分呈负相关;髓系FoxO1缺陷小鼠更易出现B细胞功能障碍。机制上FoxO1通过结合启动子区抑制Met转录,FoxO1缺陷阻断Met/环氧合酶2/前列腺素E2通路,促进B细胞增殖与过度活化,Met拮抗剂卡马替尼可减轻狼疮加重;ALKBH5介导的m6A修饰上调FoxO1可改善狼疮进展。作者认为靶向M-MDSCs中ALKBH5/FoxO1/Met轴可能为SLE提供新的治疗途径。
要点
- SLE患者与狼疮小鼠的M-MDSCs中FoxO1低表达,且与SLE疾病活动指数评分呈负相关。
- 髓系FoxO1缺陷小鼠更易出现B细胞功能障碍,FoxO1通过结合Met启动子区抑制其转录。
- ALKBH5过表达介导的M-MDSCs FoxO1上调改善狼疮进展,Met拮抗剂卡马替尼减轻狼疮加重。
核心结论
- 作者认为,有效抑制由M-MDSCs中ALKBH5/FoxO1/Met轴介导的B细胞,可能为管理SLE提供新的治疗途径。
研究设计与样本
- 研究使用GEO数据集与临床队列验证FoxO1表达及循环M-MDSCs的临床意义,并用Cre-LoxP技术构建髓系FoxO1缺陷小鼠(mFoxO1-/-)建立狼疮倾向模型。
- 采用染色质免疫沉淀测序结合转录组分析、荧光素酶报告基因实验与染色质免疫沉淀定量聚合酶链反应评估转录阶段。
- 采用甲基化RNA免疫沉淀测序、RNA测序与CRISPR-dCas9鉴定N6-腺苷酸甲基化(m6A)修饰。
- 开展体外B细胞共培养实验、卡马替尼灌胃给药、m6A调控的MDSCs过继转移及SLE患者样本验证。
主要发现
- 低FoxO1主要表达于SLE患者与狼疮小鼠的M-MDSCs中,髓系FoxO1缺陷小鼠(mFoxO1-/-)更易发生B细胞功能障碍。
- 机制上FoxO1通过结合启动子区抑制间充质-上皮转化因子蛋白(Met)转录;M-MDSCs FoxO1缺陷阻断Met/环氧合酶2/前列腺素E2分泌通路,促进B细胞增殖与过度活化。
- Met拮抗剂卡马替尼有效减轻狼疮加重。
- ALKBH5靶向催化FoxO1信使RNA编码序列与3'非翻译区上的m6A修饰;M-MDSCs中ALKBH5过表达介导的FoxO1上调改善狼疮进展。
- 这些相关性在未经治疗的SLE患者中得到确认。
临床怎么用
- 作者认为,有效抑制由M-MDSCs中ALKBH5/FoxO1/Met轴介导的B细胞,可能为管理SLE提供新的治疗途径。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Myeloid-derived suppressor cells (MDSCs) contribute to the pathogenesis of systemic lupus erythematosus (SLE), in part due to promoting the survival of plasma cells. FoxO1 expression in monocytic MDSCs (M-MDSCs) exhibits a negative correlation with the SLE Disease Activity Index score. This study aimed to investigate the hypothesis that M-MDSC-specific FoxO1 deficiency enhances aberrant B cell function in aggressive SLE. METHODS: We used GEO data sets and clinical cohorts to verify the clinical significance of FoxO1 expression and circulating M-MDSCs. Using Cre-LoxP technology, we generated myeloid FoxO1 deficiency mice (mFoxO1-/-) to establish murine lupus-prone models. The transcriptional stage was assessed by integrating chromatin immunoprecipitation (ChIP)-sequencing with transcriptomic analysis, luciferase reporter assay, and ChIP-quantitative polymerase chain reaction. Methylated RNA immunoprecipitation sequencing, RNA sequencing, and CRISPR-dCas9 were used to identify N6-adenosine methylation (m6A) modification. In vitro B cell coculture experiments, capmatinib intragastric administration, m6A-modulated MDSCs adoptive transfer, and sample validation of patients with SLE were performed to determine the role of FoxO1 on M-MDSCs dysregulation during B cell autoreacted with SLE. RESULTS: We present evidence that low FoxO1 is predominantly expressed in M-MDSCs in both patients with SLE and lupus mice, and mice with myeloid FoxO1 deficiency (mFoxO1-/-) are more prone to B cell dysfunction. Mechanically, FoxO1 inhibits mesenchymal-epithelial transition factor protein (Met) transcription by binding to the promoter region. M-MDSCs FoxO1 deficiency blocks the Met/cyclooxygenase2/prostaglandin E2 secretion pathway, promoting B cell proliferation and hyperactivation. The Met antagonist capmatinib effectively mitigates lupus exacerbation. Furthermore, alkB homolog 5 (ALKBH5) targeting catalyzes m6A modification on FoxO1 messenger RNA in coding sequences and 3' untranslated regions. The up-regulation of FoxO1 mediated by ALKBH5 overexpression in M-MDSCs improves lupus progression. Finally, these correlations were confirmed in untreated patients with SLE. CONCLUSION: Our findings indicate that effective inhibition of B cells mediated by the ALKBH5/FoxO1/Met axis in M-MDSCs could offer a novel therapeutic approach to manage SLE.
引用
- Tan L, Kong W, Zhou K, et al. FoxO1 Deficiency in Monocytic Myeloid-Derived Suppressor Cells Exacerbates B Cell Dysfunction in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2024. PMID: 39492682. doi:10.1002/art.43046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。